Nuformix plc (LON:NFX) Executive Director Dan Gooding joins DirectorsTalk to discuss an update on its NXP002 study results.
Dan is delighted to remind us of what the NXP002 programme is and its purpose, take us through the key findings and explains the next steps following the success achieved.
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing.
